» Authors » S E Grossberg

S E Grossberg

Explore the profile of S E Grossberg including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 115
Citations 1167
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kauffman M, Sterin-Prync A, Papouchado M, Gonzalez E, Vidal A, Grossberg S, et al.
Int J Immunopathol Pharmacol . 2011 Jun; 24(2):499-504. PMID: 21658324
In order to determine whether Blastoferon®, a biosimilar interferon (IFN)- beta 1a formulation, shares epitopes with other known IFN-beta products, a series of neutralization bioassays were performed with a set...
2.
Lallemand C, Meritet J, Erickson R, Grossberg S, Roullet E, Lyon-Caen O, et al.
J Interferon Cytokine Res . 2008 Jul; 28(6):393-404. PMID: 18593334
Development of neutralizing antibodies (NAbs) to interferons (IFNs) can reduce the clinical response to IFN therapy. As current cell-based assays for quantifying NAbs have limitations, a highly sensitive and reproducible...
3.
Boz C, Oger J, Gibbs E, Grossberg S
Mult Scler . 2007 Oct; 13(9):1127-37. PMID: 17967840
Multiple sclerosis (MS) patients treated with interferon-beta (IFN-beta) often form anti-IFN-beta antibodies accompanied by a reduction in IFN-beta bioavailability. The clinical effect of these antibodies remains controversial. MS patients in...
4.
Runkel L, de Dios C, Karpusas M, Baker D, Li Z, Zafari M, et al.
J Interferon Cytokine Res . 2001 Dec; 21(11):931-41. PMID: 11747625
The epitopes important for receptor binding and activation of human interferon-beta1a (IFN-beta1a) were mapped with monoclonal antibodies (mAb), grouped on the basis of their specificity and ability to neutralize biologic...
5.
Grossberg S, KAWADE Y, Kohase M, Klein J
J Interferon Cytokine Res . 2001 Sep; 21(9):743-55. PMID: 11576468
The importance of establishing a common method of reporting neutralizing antibody levels is emphasized by the fact that patients injected repeatedly with a human interferon (HuIFN) may develop such antibodies...
6.
Grossberg S, KAWADE Y, Kohase M, Yokoyama H, Finter N
J Interferon Cytokine Res . 2001 Sep; 21(9):729-42. PMID: 11576467
The highly specific ability of antibodies to inhibit the biologic activity of cytokines or other therapeutic proteins is widely used in research and a subject of increasing clinical importance. The...
7.
Osorio J, Grossberg S, Palmenberg A
Viral Immunol . 2000 Mar; 13(1):27-35. PMID: 10733166
We have shown that genetically engineered mengoviruses containing artificially shortened 5' noncoding poly(C) tracts (e.g., C0 or C13UC10) are dramatically attenuated in adult Swiss/ICR mice when compared to wild-type virus...
8.
Golgher R, Redlich P, Totti D, Grossberg S
J Interferon Cytokine Res . 1999 Oct; 19(9):995-8. PMID: 10505740
We have developed a new liquid-phase, chemiluminescence-enhanced, inhibition ELISA (LP-CEI-ELISA) to explore the binding sites recognized by two neutralizing monoclonal antibodies (mAb) against recombinant human IFN-(beta)ser (rHuIFN-(beta)ser). In this assay,...
9.
Pungor Jr E, Files J, Gabe J, Do L, Foley W, Gray J, et al.
J Interferon Cytokine Res . 1999 Jan; 18(12):1025-30. PMID: 9877445
We have adapted the new MxA gene-induction bioassay to measure neutralizing antibodies to interferon-beta1b (IFN-beta1b, the active ingredient in Betaseron) in sera from patients treated with Betaseron. This antibody assay...
10.
Raisch K, Kushnaryov V, Grossberg S, Cashdollar L
Virology . 1998 Oct; 250(1):135-9. PMID: 9770427
During the screening of human lymphoblastoid cells as suitable hosts for retrovirus transmission studies, the Epstein-Barr virus (EBV)-negative, B-lymphoblastoid cell line DG-75 was found to be chronically infected with a...